Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Becherini Carlotta, Banini Marco, Blanchard Pierre, Brana Irene, Chua Melvin L K, Eriksen Jesper Grau, Huang Shao Hui, Gregoire Vincent, Licitra Lisa, Locati Laura Deborah, Ma Brigette, Machiels Jean-Pascal, Saintigny Pierre, Tinhofer Ingeborg, Livi Lorenzo, Bossi Paolo, Harrington Kevin J, Bonomo Pierluigi
Аннотация
BACKGROUND: Integration of radiation therapy (RT) with systemic treatments in head and neck cancers has transformed therapeutic paradigms, yet optimal combinations remain undefined. This study aimed to identify priority areas of unmet need in combining RT with systemic treatment in both squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC).
METHODS: A multidisciplinary panel of international experts in radiation, clinical, and medical oncology convened to identify priority areas of unmet need. Four clinical scenarios were evaluated: locally-advanced (LA) SCCHN; recurrent/metastatic (R/M) SCCHN; LA NPC; and R/M NPC. Experts ranked a predefined shortlist of topics using weighted Borda count methodology and proposed ideal clinical trial designs to address the identified unmet needs.
RESULTS: Fifteen expert responses identified eight priority topics across the four scenarios. In locally-advanced SCCHN, top priorities included risk-adapted prognostic evaluation at diagnosis and personalized chemoradiation following peri-operative immunotherapy. For R/M SCCHN, experts highlighted the role of locoregional radiation in de-novo metastatic disease on first-line therapy and treatment sequencing in oligometastatic programmed death ligand-1 (PD-L1) combined positive score (CPS)-positive disease as the key need. In LA NPC, the leading topics were patient selection for intensification strategies and for de-escalation after induction chemo-immunotherapy. In R/M NPC, experts prioritized sequencing locoregional RT and metastasis-directed therapy in patients with de-novo oligometastatic disease who are benefiting from first-line treament.
CONCLUSIONS: This study defines critical knowledge gaps in integrating RT with systemic treatments in head and neck cancer, and provides a roadmap for future international consensus development and clinical research to advance personalized treatment strategies.
METHODS: A multidisciplinary panel of international experts in radiation, clinical, and medical oncology convened to identify priority areas of unmet need. Four clinical scenarios were evaluated: locally-advanced (LA) SCCHN; recurrent/metastatic (R/M) SCCHN; LA NPC; and R/M NPC. Experts ranked a predefined shortlist of topics using weighted Borda count methodology and proposed ideal clinical trial designs to address the identified unmet needs.
RESULTS: Fifteen expert responses identified eight priority topics across the four scenarios. In locally-advanced SCCHN, top priorities included risk-adapted prognostic evaluation at diagnosis and personalized chemoradiation following peri-operative immunotherapy. For R/M SCCHN, experts highlighted the role of locoregional radiation in de-novo metastatic disease on first-line therapy and treatment sequencing in oligometastatic programmed death ligand-1 (PD-L1) combined positive score (CPS)-positive disease as the key need. In LA NPC, the leading topics were patient selection for intensification strategies and for de-escalation after induction chemo-immunotherapy. In R/M NPC, experts prioritized sequencing locoregional RT and metastasis-directed therapy in patients with de-novo oligometastatic disease who are benefiting from first-line treament.
CONCLUSIONS: This study defines critical knowledge gaps in integrating RT with systemic treatments in head and neck cancer, and provides a roadmap for future international consensus development and clinical research to advance personalized treatment strategies.